Home・Список акций・Puma Biotechnology Inc

Puma Biotechnology Inc

Закрыт

СекторЗдравоохранение

7.99 2.96

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

7.75

Макс.

8.07

Ключевые показатели
By Trading Economics
Доход	-16M -3.8M
Продажи	-31M 45M
P/E Средняя по отрасли	16.521 68.51
Прибыль на акцию	-0.04
Рентабельность продаж	-8.375
Сотрудники	179
EBITDA	-27M -196K

Рекомендации
By TipRanks
Рекомендации	Нейтрально
Прогноз на 12 месяцев	-35.9% downside

Дивиденды
By Acuity
Следующий отчет о доходах	6 авг. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	20M 404M
Предыдущая цена открытия	5.03
Предыдущая цена закрытия	7.99

Новостные настроения

By Acuity

50%

175 / 340 Рейтинг в Healthcare

Puma Biotechnology Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

4 авг. 2026 г., 19:56 UTC

Puma Biotechnology Inc is trading higher today, benefiting from a decline in crude oil prices that eased inflation concerns. Shares earlier pulled back from a session high.

3 авг. 2026 г., 19:51 UTC

Puma Biotechnology Inc shares are lower today, reflecting a decline since Friday. The stock saw significant volatility, initially rising before dropping sharply.

31 июл. 2026 г., 19:16 UTC

Puma Biotechnology Inc shares are lower today, continuing a decline since Thursday's close. The stock is trading near the lower end of its one-month range.

30 июл. 2026 г., 18:31 UTC

Puma Biotechnology Inc shares are higher as the overall market recovers from recent declines. The stock remains below its 20-day moving average.

29 июл. 2026 г., 18:23 UTC

Puma Biotechnology Inc shares are lower amid broader market weakness as investors await the Federal Reserve's interest rate decision this afternoon.

28 июл. 2026 г., 18:06 UTC

Puma Biotechnology shares are lower amid broader market trends, influenced by declines in Asian markets, particularly in technology sectors.

27 июл. 2026 г., 19:46 UTC

Puma Biotechnology Inc shares are higher, reflecting broader market gains amid a significant decline in crude oil prices following geopolitical developments.

24 июл. 2026 г., 19:26 UTC

Puma Biotechnology Inc. shares are roughly flat as no specific news emerged during Friday's trading session, fluctuating within a routine range.

23 июл. 2026 г., 20:06 UTC

Puma Biotechnology Inc shares are higher during Thursday's session, continuing an upward trend since Wednesday's close amid no specific news identified.

22 июл. 2026 г., 22:51 UTC

Puma Biotechnology Inc shares are trading higher in after-market hours, building on earlier gains. The stock remains above its 20-day moving average.

21 июл. 2026 г., 18:02 UTC

Puma Biotechnology Inc shares are higher during Tuesday's session, continuing a positive trend since Monday. The stock remains above its 20-day moving average.

20 июл. 2026 г., 20:06 UTC

Puma Biotechnology Inc shares are lower today, having reached a mid-day low of -4.46%. No specific news has been identified to explain the decline.

Сравнение c конкурентами

Изменение цены

Puma Biotechnology Inc Прогноз

Целевая цена

By TipRanks

-35.9% падение

Прогноз на 12 месяцев

Средняя 5 USD -35.9%

Максимум 5 USD

Минимум 5 USD

Основано на мнении 1 аналитиков Wall Street, спрогнозировавших целевые цены для Puma Biotechnology Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Нейтрально

1 ratings

Покупка

Удержание

Продажа

Основано на мнении 1 аналитиков, присваивавших рейтинги акциям Puma Biotechnology Inc – Данные за последние 3 месяца.

Настроения

By Acuity

175 / 340Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.